New study: One in 5 COVID-19 patients develop mental illness within 90 days

New study: One in 5 COVID-19 patients develop mental illness within 90 days

- More research studies on the coronavirus are being published

- A new study indicates that survivors of the infection might develop mental illness

- The researchers are from Britain’s Oxford University and their findings were published in The Lancet Psychiatry journal

PAY ATTENTION: Win a prize of N115,000, N75000 or N38000: participate in Big Naija Independence contest by

A new study has revealed that many COVID-19 survivors are likely to be at greater risk of developing mental illness.

This was predicted by psychiatrists Monday, November 9 after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.

Anxiety, depression, and insomnia were most common among recovered COVID-19 patients in the study who developed mental health problems.

Reuters reports that the researchers from Britain’s Oxford University also found significantly higher risks of dementia, a brain impairment condition.

Pfizer/BioNtech coronavirus vaccine: Price to vary in countries and regions
New study: One in 5 COVID-19 patients develop mental illness within 90 days

The researchers are mainly from the prestigious Oxford University. Photo credit: @UniofOxford
Source: Twitter

PAY ATTENTION: Get the Latest Nigerian News Anywhere 24/7. Spend less on the Internet!

The study, published in The Lancet Psychiatry journal, analysed electronic health records of 69 million people.

Reactions have been trailing the result of the research as social media users have been commenting on the findings.

Brodie Riske wrote on Twitter:

“For those wondering, COVID affects the RNA in our bodies. RNA controls the proteins that are converted from DNA.
“An imbalance of these proteins can cause the mentioned mental illnesses, including dementia.”

Adam Crabtree wrote:

“I'd like to think the shutdowns, uncertainty, and overall fear of the pandemic, in general, has led to depression and mental illness in a lot more than just people who contracted the virus. This seems like a difficult study to conduct.”

In a related development, Pfizer/BioNTech has revealed the first interim results in large-scale trials that its vaccine, which is in its phase 3 trial, is 90% effective and that the vaccine would be sold at different prices between countries and regions.

Breaking: President Buhari welcomes COVID-19 vaccine, says how it must be distributed

Ryan Richardson, the head of strategy for the biotech firm, said the organisation is planning to put the price of the serum below typical market rates.

Following the announcement of a COVID-19 vaccine, President Muhammadu Buhari has welcomed the arrival of the first effective serum after a successful human trial phase.

While describing it as a major milestone, Buhari went on to call for equal distribution and access to the vaccine.

Covid-19: Trump fulfills promise to Nigeria, presents 200 Ventilators to health ministry | Legit TV

Source: News

Online view pixel